Cerus Co. (NASDAQ:CERS) Short Interest Update

by · The Cerbat Gem

Cerus Co. (NASDAQ:CERS – Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 7,040,000 shares, an increase of 6.2% from the September 15th total of 6,630,000 shares. Based on an average daily trading volume, of 1,000,000 shares, the short-interest ratio is currently 7.0 days.

Insider Buying and Selling at Cerus

In other news, insider Richard J. Benjamin sold 21,605 shares of the business’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $2.50, for a total value of $54,012.50. Following the completion of the sale, the insider now owns 438,007 shares of the company’s stock, valued at approximately $1,095,017.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Kevin Dennis Green sold 28,385 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the sale, the chief financial officer now owns 590,365 shares of the company’s stock, valued at approximately $1,286,995.70. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Richard J. Benjamin sold 21,605 shares of Cerus stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $2.50, for a total transaction of $54,012.50. Following the completion of the transaction, the insider now directly owns 438,007 shares in the company, valued at approximately $1,095,017.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

Hedge Funds Weigh In On Cerus

Several hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company raised its position in shares of Cerus by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 7,209 shares in the last quarter. Creative Planning grew its stake in Cerus by 51.3% in the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 8,411 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Cerus by 4.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 8,982 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in Cerus by 38.4% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,074 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 9,737 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Cerus by 4.4% during the 2nd quarter. Rhumbline Advisers now owns 252,444 shares of the biotechnology company’s stock valued at $444,000 after buying an additional 10,739 shares in the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.

Cerus Price Performance

Cerus stock remained flat at $1.80 during trading hours on Wednesday. 1,323,999 shares of the company’s stock were exchanged, compared to its average volume of 1,195,036. The company’s 50 day simple moving average is $2.00 and its two-hundred day simple moving average is $1.93. Cerus has a 1-year low of $1.21 and a 1-year high of $2.59. The stock has a market cap of $332.80 million, a PE ratio of -10.59 and a beta of 1.18. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 1.29.

Cerus (NASDAQ:CERS – Get Free Report) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. Cerus had a negative net margin of 14.15% and a negative return on equity of 44.27%. The company had revenue of $45.08 million during the quarter, compared to analyst estimates of $42.50 million. During the same period in the prior year, the business posted ($0.07) earnings per share. Research analysts predict that Cerus will post -0.13 earnings per share for the current fiscal year.

About Cerus

(Get Free Report)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

See Also